Flinders Meditech Pty Ltd

Details
Medical Suppliers In South Australia

Name :

Flinders Meditech Pty Ltd

Address  :

Mark Oliphant Building
Laffer Drive
Science Park Adelaide

Town  :

Bedford Park

State  :

South Australia

Country  :

AUSTRALIA

Post Code:

5042

Phone  :

61 8 8201 7718

Fax  :

61 8 8201 7888

Web URL  :

Available

Email  :

info@flindersmeditech.com
Specialization
Information not available, if you are owner/employee of Flinders Meditech Pty Ltd Please click to update hospital details.
Facilities
Information not available, if you are owner/employee of Flinders Meditech Pty Ltd Please click to update hospital details.
Description
Mission Statement
Mission
Creating superior medical training devices technologies and reagents designed to improve professional healthcare knowledge and skills and thereby reduce risks to patient safety

Our goals
Our Goals are being achieved by the integration of expertise within the School of Informatics amp Engineering and the School of Medicine at Flinders University to help create technologically advanced medical devices technologies and reagents

We will
1 Produce one advanced technology concept into
product development each year

2 Launch one advanced technology device on world
markets each year

3 Support these activities by active trial by and
promotion to opinion leaders worldwide

4 Provide funding from our profits to maintain
leading research activities in related areas

5 Ensure a commercially competitive return is earned
for our shareholders
NEWS
RDH gets record cash transfusion in NT budget

The Northern Territory Government has committed a record 335 million to Royal Darwin Hospital in this years budget Health Minister Kon Vatskalis says this is 20 million dollars more than the hospital received last year He says the extra funding will be used across the board Every single service of this hospital gets part of this budget he ... Read More

ARTICLES
Group B Neisseria meningitidis Vaccine Shows Promise

An investigational vaccine may represent a strong lead in the fight against group B Neisseria meningitidis according to results of a phase 2 study published online in the Lancet Administered in 3 doses over the course of 6 months a new bivalent vaccine was well tolerated and induced a strong immune response against multiple strains of the poten... Read More